My Blue Dots

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development. “The most important predicter of successful drug development is a team of people who have successfully developed a therapy from discovery to regulatory approval,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto.

JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative treatments for patients with age-related macular degeneration (AMD). This relationship, initiated in 2024, represents a major step forward by bringing together Bausch + Lomb’s extensive expertise in ophthalmology with Character Bio’s integrated patient data platform a

MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. “We are thrilled to have Paul assume the role of Chief Executive Officer,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “Having worked very clo

BOSTON & SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

SHANGHAI & CAMBRIDGE, Mass. & BOSTON–(BUSINESS WIRE)–Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

DUBLIN–(BUSINESS WIRE)–The “Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) – Advances & Applications, 2025” report has been added to ResearchAndMarkets.com’s offering. MSCs are multipotent cells that have been referred to as mesenchymal stem cells, medicinal signaling cells, and mesenchymal stromal cells, reflecting their versatility and diverse applications. MSCs can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their

FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics’ Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO at that time.

LONDON & NEW YORK–(BUSINESS WIRE)—- $CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one